Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2010 - 2026)
Pacific Biosciences Of California (PACB) recorded quarterly Depreciation & Amortization (CF) of $2.2 million in Q1 2026, down 19.97% quarter-over-quarter from $2.7 million in Q4 2025, and down 57.12% on a YoY basis from $5.1 million in Q1 2025.
Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 57.12% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $10.1 million (down 35.72% YoY), while the FY2025 annual figure was $13.0 million, down 5.62% from the prior year.
- Depreciation & Amortization (CF) was $2.2 million for Q1 2026 at Pacific Biosciences Of California, down from $2.7 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.1 million in Q1 2025 to a low of $2.2 million in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.8 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) soared 58.36% in 2025, then slumped 57.12% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.6 million in 2022, then increased by 17.56% to $3.0 million in 2023, then retreated by 5.68% to $2.8 million in 2024, then retreated by 3.27% to $2.7 million in 2025, then fell by 19.97% to $2.2 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 749.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 67.10 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 123.40 Mn |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 3.01 Mn |
| Dec 31, 2023 | 3.01 Mn |